Von Eschenbach in ‘07?
This article was originally published in The Gray Sheet
Executive Summary
Senate HELP Committee staffer says it is "highly unlikely" that Acting FDA Commissioner Andrew von Eschenbach, MD, will be confirmed as permanent commissioner this year. The confirmation hold initiated by Sens. Hillary Rodham Clinton (D-N.Y.) and Patty Murray (D-Wash.) stems from political wrangling over the agency's handling of emergency contraceptive drug, Plan B (1"The Gray Sheet" April 3, 2006, p. 13)...
You may also be interested in...
Plan B Backlash Blocks FDA Commissioner Nomination, Take Two
FDA will not have a permanent commissioner until a decision is announced on over-the-counter sales of Barr's emergency contraceptive Plan B, if a hold by Senate Democrats is respected
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.